Market News AIOpen the app

CRDF stock news · Cardiff Oncology, Inc.

Stories about Cardiff Oncology, Inc. (CRDF) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CRDF

Follow Cardiff Oncology, Inc. (CRDF) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRDF
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 9:08 AM ET · Trial

    Cardiff Oncology got FDA Fast Track approval for its drug onvansertib to treat a type of colon cancer.

    Good for CRDF

    Cardiff Oncology received FDA Fast Track designation for onvansertib; its trial showed a 72.2% response rate versus 42.1% with the comparison treatment. This is positive, though approval remains ahead.